Liquid biopsy: monitoring cancer-genetics in the blood
Top Cited Papers
- 9 July 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 10 (8), 472-484
- https://doi.org/10.1038/nrclinonc.2013.110
Abstract
Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations is increasingly used for diagnostic, prognostic and treatment purposes. The genetic profile of solid tumours is currently obtained from surgical or biopsy specimens; however, the latter procedure cannot always be performed routinely owing to its invasive nature. Information acquired from a single biopsy provides a spatially and temporally limited snap-shot of a tumour and might fail to reflect its heterogeneity. Tumour cells release circulating free DNA (cfDNA) into the blood, but the majority of circulating DNA is often not of cancerous origin, and detection of cancer-associated alleles in the blood has long been impossible to achieve. Technological advances have overcome these restrictions, making it possible to identify both genetic and epigenetic aberrations. A liquid biopsy, or blood sample, can provide the genetic landscape of all cancerous lesions (primary and metastases) as well as offering the opportunity to systematically track genomic evolution. This Review will explore how tumour-associated mutations detectable in the blood can be used in the clinic after diagnosis, including the assessment of prognosis, early detection of disease recurrence, and as surrogates for traditional biopsies with the purpose of predicting response to treatments and the development of acquired resistance.Keywords
This publication has 156 references indexed in Scilit:
- Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersBreast Cancer Research and Treatment, 2012
- Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancerEuropean Journal of Surgical Oncology, 2011
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsLung Cancer, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsGenes, Chromosomes and Cancer, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Influence of neuroblastoma stage on serum‐based detection of MYCN amplificationPediatric Blood & Cancer, 2009
- Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancerCancer Letters, 2008
- Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patientsInternational Journal of Cancer, 2007
- Autoimmunity versus tolerance: Can dying cells tip the balance?Clinical Immunology, 2007